Table 1 Baseline characteristics of the general population, MDT group and non-MDT group
From: The role of a multidisciplinary team in the management of portal hypertension
|  | Global Population (n = 528) | MDT (n = 86) | Non-MDT (n = 442) |
|---|---|---|---|
General Characteristics | |||
Gender | |||
 Male | 351 (66.5%) | 59 (68.6%) | 292 (66.1%) |
 Female | 177 (33.5%) | 27 (31.4%) | 150 (33.9%) |
Age (years) | 53.51 ± 10.99 | 52.91 ± 13.08 | 53.63 ± 10.55 |
Child Pugh Score | 6.70 ± 1.45 | 6.59 ± 1.32 | 6.72 ± 1.47 |
Child Pugh Classification | |||
 Class A | 268 (50.8%) | 44 (51.2%) | 224 (50.7%) |
 Class B | 240 (45.5%) | 41 (47.7%) | 199 (45%) |
 Class C | 20 (3.8%) | 1 (1.2%) | 19 (4.3%) |
MELD Score | 6.65 ± 4.29 | 7.04 ± 4.59 | 6.57 ± 4.23 |
HVPG (n = 135) | 13.78 ± 7.33 | 12.96 ± 7.10 | 15.04 ± 7.56 |
Etiology of Portal Hypertension | |||
 HBV | 290 (54.9%) | 44 (51.2%) | 246 (55.7%) |
 HCV | 10 (1.9%) | 2 (2.3%) | 8 (1.8%) |
 Alcohol | 44 (8.4%) | 4 (4.7%) | 40 (9%) |
 PBC | 4 (0.8%) | 2 (2.3%) | 2 (0.5%) |
 AIH | 55 (10.4%) | 3 (3.5%) | 52 (11.8%) |
 Schistosomiasis | 28 (5.3%) | 9 (10.5%) | 19 (4.3%) |
 Cryptogenic | 68 (12.9) | 6 (7.0%) | 62 (14%) |
 NAFLD | 1 (0.2%) | 0 (0%) | 1 (0.2%) |
 Others | 16 (3.0%) | 13 (15.1%) | 3 (0.7%) |
 Mixed | 12 (2.3%) | 3 (3.5%) | 9 (2%) |
Laboratory Parameters | |||
 Hemoglobin (g/L) | 86.50 (72.00–104.00) | 93.50 (76.25–117.75) | 88.31 85 (71.00–102.00) |
 Platelet (× 109/L) | 61.00 (43.00–83.25) | 65 (39.25–114.75) | 61.00 (44.00–80.00) |
 White blood cell (× 109/L) | 2.74 (2.03–3.80) | 2.83 (2.02–3.89) | 2.73 (2.03–3.78) |
 Total Bilirubin (μmol/L) | 14.55 (10.58–21.50) | 14.25 (10.43–21.7) | 14.65 (10.63–21.48) |
 ALT (U/L) | 24.00 (16.85–36.00) | 19.50 (15.00–27.00) | 25.00 (17.00–40.00) |
 AST (U/L) | 32.00 (24.00–44.00) | 29.00 (21.25–38.75) | 33.00 (24.55–44.00) |
 Albumin (g/L) | 34.00 (30.00–38.00) | 36.00 (32.00–40.00) | 34.00 (30.00–38.00) |
 Serum Creatinine (μmol/L) | 67.00 (57.00–79.00) | 67.00 (58.00–77.75) | 67.00 (57.00–79.53) |
 Prothrombin Time (s) | 14.10 (13.10–15.40) | 13.80 (12.93–15.25) | 14.10 (13.20–15.40) |
 International Normalized Ratio (INR) | 1.22 (1.14–1.33) | 1.23 (1.14–1.35) | 1.22 (1.13–1.33) |
Received Previous Treatment | 132 (64.5%) | 37 (43.0%) | 95 (21.5%) |
Concurrent Conditions | |||
Portal Venous Thrombosis | |||
 Absent | 431 (81.6%) | 53 (61.6%) | 351 (79.4%) |
 Present | 97 (18.4%) | 33 (38.4%) | 91 (20.6%) |
Hepatic Cellular Carcinoma | |||
 Absent | 490 (92.8%) | 77 (89.5%) | 413 (93.4%) |
 Present | 38 (7.2%) | 9 (10.5%) | 29 (6.6%) |
Ascites | |||
 Absent | 253 (47.9%) | 45 (52.3%) | 208 (47.1%) |
 Mild | 232 (43.9%) | 40 (46.5%) | 192 (43.5%) |
 Severe | 43 (8.1%) | 1 (1.2%) | 42 (9.5%) |
Endoscopic Examination | |||
Gastroesophageal Classification | |||
 EV | 149 (28.2%) | 16 (18.6%) | 133 (30.1%) |
 GOV Type 1 | 298 (56.4%) | 23 (26.7%) | 275 (62.2%) |
 GOV Type 2 | 48 (9.1%) | 30 (34.9%) | 18 (4.1%) |
 IGV Type 1 | 33 (6.3%) | 17 (19.8%) | 16 (3.6%) |
Treatment Received | |||
 Pharmacological Treatment | 20 (3.8%) | 12 (14%) | 8 (1.8%) |
 Endoscopy | 403 (76.3%) | 28 (32.6%) | 375 (84.8%) |
 Surgery | 55 (10.4%) | 7 (8.1%) | 48 (10.9%) |
 Interventional Radiology | 45 (8.5%) | 37 (43%) | 8 (1.8%) |
 Combined Therapy | 5 (9.0%) | 2 (2.3%) | 3 (0.7%) |
Follow-up | |||
 Variceal Rebleed | 156 (29.5%) | 7 (8.1%) | 149 (33.7%) |
 Time to Rebleed | 521.40 (299.75–989.70) | 382.50 (289.50–508.25) | 579.30 (301.35–1062.60) |
 Mortality | 86 (16.3%) | 9 (10.5%) | 77 (17.4%) |
 Time to Death | 728.25 (420.68–1198.58) | 382.50 (289.50–508.25) | 843.15 (467.40–1368.00) |